Published On: Wed, Oct 19th, 2016

Broker Changes For Loxo Oncology, Inc. (LOXO)


Recently stock market analysts have updated their consensus ratings on shares of Loxo Oncology, Inc. (LOXO).

Most recent broker ratings

04/18/2016 – Loxo Oncology, Inc. had its “outperform” rating reiterated by analysts at Oppenheimer. They now have a USD 30 price target on the stock.

04/18/2016 – Loxo Oncology, Inc. had its “buy” rating reiterated by analysts at Stifel Nicolaus. They now have a USD 36 price target on the stock.

01/15/2016 – Citigroup began new coverage on Loxo Oncology, Inc. giving the company a “buy” rating. They now have a USD 32 price target on the stock.

10/15/2015 – Loxo Oncology, Inc. had its “outperform” rating reiterated by analysts at Cowen.

09/02/2014 – Leerink Swann began new coverage on Loxo Oncology, Inc. giving the company a “outperform” rating. They now have a USD 20 price target on the stock.

08/26/2014 – JMP Securities began new coverage on Loxo Oncology, Inc. giving the company a “outperform” rating. They now have a USD 23 price target on the stock.

Loxo Oncology, Inc. has a 50 day moving average of 25.46 and a 200 day moving average of 25.24. The stock’s market capitalization is 469.46M, it has a 52-week low of 16.36 and a 52-week high of 35.00.

The share price of the company (LOXO) was up +2.56% during the last trading session, with a high of 22.03 and the volume of Loxo Oncology, Inc. shares traded was 50292.

Loxo Oncology, Inc. is a United States-based biopharmaceutical company. The Company is engaged in developing selective medicines for patients with genetically defined cancers. Its pipeline focuses on cancers that are dependent on single gene abnormalities, such that a single drug has the potential to treat the cancer. Its pipeline includes LOXO-101, LOXO-195, Rearranged During Transfection (RET) Program and Fibroblast Growth Factor Receptor (FGFR) program. LOXO-101 is a selective inhibitor of tropomyosin receptor kinases (TRK) for the treatment of patients with soft tissue sarcoma. LOXO-195 is a selective TRK inhibitor capable of addressing potential mechanisms of acquired resistance that may emerge in patients receiving LOXO-101 or multikinase inhibitors with anti-TRK activity. It has designed a series of RET inhibitors that optimize on-target potency for RET gene fusions, mutations and clinically-identified resistance mutations. It is designing FGFR1-sparing FGFR inhibitor.